FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591550189> ?p ?o ?g. }

• W2591550189 endingPage "258" @default.
• W2591550189 startingPage "245" @default.
• W2591550189 abstract "Background Bevacizumab is a humanised monoclonal antibody which blocks the binding of circulating vascular endothelial growth factor to its receptors. To date, the Food and Drug Administration has approved bevacizumab for the treatment of several solid tumours. To assess the impact of bevacizumab-based regimens on outcome in these advanced solid tumour types, we performed a meta-analysis. We included all of the randomised trials (phase II or III) where bevacizumab was tested in the first line setting compared with a control arm, including chemotherapy, placebo or other anti-neoplastic agents. Methods A literature-based meta-analysis of randomised controlled trials (RCTs) in accordance with the preferences for reported items in systematic reviews and meta-analyses guidelines were undertaken. The primary end-point considered was overall survival (OS). The secondary end-points were progression-free survival (PFS) time, response rate and safety. A subgroup analysis was performed to highlight any differences between studies in different tumour types for all end-points. Results The pooled analysis from RCTs on bevacizumab-based regimens revealed significantly increased OS (hazard ratio [HR] for death 0.92, 95% confidence interval [CI]: 0.88–0.95; P < 0.0001), PFS (HR: 0.72, 95% CI: 0.67–0.78; P < 0.00001) and response rate (risk ratio: 1.38, 95% CI: 1.27–1.50; P < 0.00001) compared to control arm in solid tumours overall and in colorectal, lung, ovarian and renal cancer as single indications. However, notably, no effect on survival was seen in breast cancer. Conclusion This study confirmed that bevacizumab-based regimens result in a significant effect on survival and response in advanced colorectal, lung, ovarian and kidney cancer. In cancers where bevacizumab failed overall as in breast cancer, a dedicated biomarkers analysis is warranted to select the proper subgroup of patient that might have the adequate clinical benefit." @default.
• W2591550189 created "2017-03-03" @default.
• W2591550189 creator A5003897511 @default.
• W2591550189 creator A5020078965 @default.
• W2591550189 creator A5037756908 @default.
• W2591550189 creator A5041410352 @default.
• W2591550189 creator A5047413929 @default.
• W2591550189 creator A5047713528 @default.
• W2591550189 creator A5060773546 @default.
• W2591550189 date "2017-04-01" @default.
• W2591550189 modified "2023-09-24" @default.
• W2591550189 title "The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials" @default.
• W2591550189 cites W1925212740 @default.
• W2591550189 cites W1986215651 @default.
• W2591550189 cites W1994014733 @default.
• W2591550189 cites W2040253672 @default.
• W2591550189 cites W2048067273 @default.
• W2591550189 cites W2053083499 @default.
• W2591550189 cites W2053284036 @default.
• W2591550189 cites W2081367341 @default.
• W2591550189 cites W2085946496 @default.
• W2591550189 cites W2099279915 @default.
• W2591550189 cites W2099998343 @default.
• W2591550189 cites W2100756525 @default.
• W2591550189 cites W2102306754 @default.
• W2591550189 cites W2103563357 @default.
• W2591550189 cites W2105683151 @default.
• W2591550189 cites W2107328434 @default.
• W2591550189 cites W2112759697 @default.
• W2591550189 cites W2113122060 @default.
• W2591550189 cites W2114159573 @default.
• W2591550189 cites W2115005218 @default.
• W2591550189 cites W2115330744 @default.
• W2591550189 cites W2115898240 @default.
• W2591550189 cites W2122152991 @default.
• W2591550189 cites W2124736921 @default.
• W2591550189 cites W2125435699 @default.
• W2591550189 cites W2126275851 @default.
• W2591550189 cites W2128095147 @default.
• W2591550189 cites W2135140316 @default.
• W2591550189 cites W2135947389 @default.
• W2591550189 cites W2137417501 @default.
• W2591550189 cites W2140103603 @default.
• W2591550189 cites W2142573198 @default.
• W2591550189 cites W2143743735 @default.
• W2591550189 cites W2144915560 @default.
• W2591550189 cites W2145708352 @default.
• W2591550189 cites W2145835533 @default.
• W2591550189 cites W2153211112 @default.
• W2591550189 cites W2153628956 @default.
• W2591550189 cites W2153982924 @default.
• W2591550189 cites W2155167083 @default.
• W2591550189 cites W2155338842 @default.
• W2591550189 cites W2156330848 @default.
• W2591550189 cites W2156537375 @default.
• W2591550189 cites W2160373161 @default.
• W2591550189 cites W2160452234 @default.
• W2591550189 cites W2160476851 @default.
• W2591550189 cites W2163003060 @default.
• W2591550189 cites W2165088640 @default.
• W2591550189 cites W2167224460 @default.
• W2591550189 cites W2167352270 @default.
• W2591550189 cites W2168236082 @default.
• W2591550189 cites W2168579528 @default.
• W2591550189 cites W2170928115 @default.
• W2591550189 cites W2171658624 @default.
• W2591550189 cites W2315123323 @default.
• W2591550189 cites W2468227431 @default.
• W2591550189 cites W2633403957 @default.
• W2591550189 cites W4252851641 @default.
• W2591550189 cites W4294215472 @default.
• W2591550189 doi "https://doi.org/10.1016/j.ejca.2017.01.026" @default.
• W2591550189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28242502" @default.
• W2591550189 hasPublicationYear "2017" @default.
• W2591550189 type Work @default.
• W2591550189 sameAs 2591550189 @default.
• W2591550189 citedByCount "73" @default.
• W2591550189 countsByYear W25915501892017 @default.
• W2591550189 countsByYear W25915501892018 @default.
• W2591550189 countsByYear W25915501892019 @default.
• W2591550189 countsByYear W25915501892020 @default.
• W2591550189 countsByYear W25915501892021 @default.
• W2591550189 countsByYear W25915501892022 @default.
• W2591550189 countsByYear W25915501892023 @default.
• W2591550189 crossrefType "journal-article" @default.
• W2591550189 hasAuthorship W2591550189A5003897511 @default.
• W2591550189 hasAuthorship W2591550189A5020078965 @default.
• W2591550189 hasAuthorship W2591550189A5037756908 @default.
• W2591550189 hasAuthorship W2591550189A5041410352 @default.
• W2591550189 hasAuthorship W2591550189A5047413929 @default.
• W2591550189 hasAuthorship W2591550189A5047713528 @default.
• W2591550189 hasAuthorship W2591550189A5060773546 @default.
• W2591550189 hasBestOaLocation W25915501892 @default.
• W2591550189 hasConcept C126322002 @default.
• W2591550189 hasConcept C141071460 @default.
• W2591550189 hasConcept C142724271 @default.
• W2591550189 hasConcept C143998085 @default.
• W2591550189 hasConcept C168563851 @default.

• next